Research progress of oncolytic herpes simplex virus in the treatment of glioma

VernacularTitle:溶瘤疱疹病毒治疗神经胶质瘤的研究进展
Author: Haijun YANG ^{1
,

2} ; Yatao WANG ; Maohua ZHENG
Author Information

1. 兰州大学第一临床医学院,甘肃兰州 730000
2. 兰州大学第一医院神经外科,甘肃兰州 730000
Keywords: Glioma; Oncolytic virus; Oncolytic herpes simplex virus; Immunotherapy
From: Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care 2023;30(6):760-764
CountryChina
Language:Chinese
Abstract: Glioma is a highly aggressive malignant tumor of the central nervous system that necessitates active treatment through surgery,radiotherapy,and chemotherapy.However,the prognosis of high-grade gliomas[World Health Organization(WHO)classification of central nervous system tumorsgrade Ⅲ-Ⅳ]remains poor,thus new treatment strategies are urgently needed.Oncolytic virus(OV)therapy is a kind of immunotherapy that can specifically infect and effectively kill tumor cells while activating anti-tumor immunity.The oncolytic herpes simplex virus(oHSV)is expected to emerge as a new adjuvant treatment for glioma due to its unique advantages.This article reviews the current understanding of oHSV,the anti-tumor mechanism of OV,the current clinical research status of oHSV targeted therapy for glioma,the research progress of oHSV collaborative anti-tumor strategy,and the existing problems in oHSV anti-glioma research,aiming to provide valuable insights for the treatment of glioma.